PATENT CLAIM ANALYSIS

Application Number: 15979770
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["544", "326000"]

Abstract:
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5  are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Claim (Index 5):
A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to  claim 1  wherein the disease is lupus nephritis.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31818
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15480787', '14441183', '15289437', '15776094', '14441193']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8410218027130556
- 35 USC 102 Novelty (BERT): 0.6097009731587797
- Combined Prediction Score: 0.817889719757628
- Mean Citation Score: 606.9376940000002
- Max Citation Score: 645.9306
- Similarity Product: 466.2103957223296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test